Topical Rapamycin: A Novel Approach to Facial Angiofibromas in Tuberous Sclerosis | Congenital Defects | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Sign In
The Cutting Edge
July 2010

Topical Rapamycin: A Novel Approach to Facial Angiofibromas in Tuberous Sclerosis

Author Affiliations


Arch Dermatol. 2010;146(7):715-718. doi:10.1001/archdermatol.2010.125

Tuberous sclerosis (TS) is a neurocutaneous disorder that can be both debilitating and disfiguring. Facial angiofibromas, a cutaneous manifestation of TS, have historically been resistant to medical and surgical treatments.1,2 These lesions are the cause of significant morbidity.

Report of a case

A 16-year-old girl presented with a complex medical history that was related to both systemic and cutaneous manifestations of TS. In addition to her cutaneous manifestations of progressive facial angiofibromas that she has had since she was 5 years old and, more recently, gingival fibromas, she also had renal angiolipomas, severe mental retardation, and epilepsy with complex partial seizures that generalize. She had been placed on a regimen of several antiepileptic medications, currently oxcarbazepine and divalproex sodium, for control of intractable seizures. At 10 months of age, she underwent open heart surgery for removal of a rhabdomyoma that was blocking her pulmonary artery. At 13 years of age, she underwent endoscopic removal of a cranial intraventrical mass, with pathologic examination demonstrating subependymal giant cell astrocytoma, followed by placement of a ventriculostomy for relief of obstructive hydrocephalus. Also, she underwent multiple shave excisions and repeated treatments with both pulsed dye and carbon dioxide lasers, with at least 1 treatment per year over the last 3 years, to control bleeding and rapid progression of facial angiofibromas. Despite these aggressive interventions, her facial lesions remained prominent, progressive, and disfiguring, with a tendency toward recurrence and new lesions. The procedural treatments had no lasting effects on the progression of her condition.

Therapeutic challenge

Facial angiofibromas, which occur in 70% to 80% of patients with TS, appear as innumerable pink papules that progressively enlarge and multiply over time. The lesions, which are highly visible markers of disease, may spontaneously bleed, impair vision, and cause emotional distress.1,2 Current treatment options for facial angiofibromas include destructive approaches such as dermabrasion, surgical excision, and laser therapy.3 A more targeted therapeutic approach is needed because current therapies are not effective in preventing early lesions and therefore may have less than satisfactory outcomes. Our patient had numerous large angiofibromas that tended to recur despite destructive approaches, and she continued to develop many new lesions at a rapid rate. Furthermore, it was necessary to balance aggressive therapy against the risk of significant permanent scarring. Also, sedation posed a high risk because of the patient's underlying seizure disorder. Some previous surgical procedures required antiepileptic loading and prolonged intubation. In light of all the risks and possible complications, the patient's recalcitrant tumors presented a significant therapeutic challenge.


Rapamycin is an immunosuppressant that is traditionally used in transplant recipients. However, this molecule also has promising antineoplastic effects that are exerted through the downregulation of angiogenesis and the correction of aberrant growth signals, which are implicated in many tumors and cancers.4,5 Recently, several studies have suggested that rapamycin therapy may be an effective treatment for the neoplasms associated with TS. For instance, oral rapamycin therapy was shown to reduce the volume of TS-associated visceral angiomyolipomas.6 Also, a patient with TS who was receiving oral rapamycin after undergoing renal transplantation had pronounced regression of her cutaneous angiofibromas.2 While systemic exposure and adverse effects would be undesirable in the treatment of cutaneous disease, a small clinical trial of topical rapamycin for psoriasis suggested that topical delivery may be feasible and safe.7 Therefore, we hypothesized that the topical application of rapamycin could be a novel and practical therapeutic option for facial angiofibromas in patients with TS.

Because a topical preparation of rapamycin is not commercially available, a 1% ointment was custom compounded for compassionate use in our patient. Rapamycin was extracted from tablets to be used for the ointment, and petrolatum was used as the major ingredient in the vehicle to minimize irritation. The compounded medication is intended for use within 3 months. Because the ointment is not produced for commercial use at this time, extended stability testing was not performed. We estimate that 0.5 g of ointment was used with each application, for a total of 5 mg of topical rapamycin.

Before beginning the topical treatment, the patient was noted to have numerous facial angiofibromas measuring approximately 0.5 to 4 mm in greatest dimension and diffusely involving the glabella and temples, with more prominent involvement of the central area of the face and the nasal bridge (Figure, A and B). Topical rapamycin therapy (1% ointment) was initiated twice daily. At 1 week, the patient's parents reported decreased erythema. Shortly thereafter, they noted gradual improvement in her skin texture. Although she could not communicate verbally, she did not appear to experience any discomfort when the medication was applied.

Photographs taken at baseline (A and B) and 12 weeks after initiation of rapamycin therapy (C and D). A and B, An examination at baseline showed multiple angiofibromas, confluent on the cheeks. C and D, An examination after 12 weeks of topical rapamycin therapy showed that the angiofibromas were reduced in number and size, with sustained effect and continued improvements in skin texture.

Photographs taken at baseline (A and B) and 12 weeks after initiation of rapamycin therapy (C and D). A and B, An examination at baseline showed multiple angiofibromas, confluent on the cheeks. C and D, An examination after 12 weeks of topical rapamycin therapy showed that the angiofibromas were reduced in number and size, with sustained effect and continued improvements in skin texture.

At the 6-week follow-up visit, the patient was noted to have a reduced number of angiofibromas and improved facial erythema. The vascular papules on both cheeks were much smaller. The lesions on the temples and forehead were completely resolved. This striking improvement had never been achieved with previous procedural treatments. At the 12-week reassessment, the patient showed a sustained effect, with continued improvement in skin texture (Figure, C and D). Laboratory tests were performed at 6 weeks and 12 weeks to evaluate potential systemic adverse effects. Complete blood cell counts and the results of a complete metabolic panel remained stable at baseline. The serum rapamycin level remained under 2 ng/mL (below the limits of detection; reference range, 4-20 ng/mL). Therefore, no measurable systemic absorption was detected after 3 months' application of 1% topical rapamycin to approximately 1% of the body surface area (BSA). Therefore, topical rapamycin therapy could be an effective treatment for facial angiofibromas, with minimal systemic toxic effects.


Rapamycin belongs to a novel group of molecules known as the mTOR (mammalian target of rapamycin) inhibitors and is approved for use in renal transplantation and drug-eluting stents in the United States. The molecular mechanisms of rapamycin are complex, and its signaling pathways have only recently been partially understood. In addition to its recognized immunosuppressive effects, this molecule demonstrates antineoplastic activity both in vitro and in vivo. Rapamycin exerts this effect by decreasing production of the proangiogenic molecule VEGF (vascular endothelial growth factor), which is implicated in many cancers, as well as by inhibiting its downstream signaling.4 Other topical immunosuppressive agents such as calcineurin inhibitors do not demonstrate these effects.8,9

Furthermore, rapamycin appears to correct aberrant signaling in a variety of pathways that regulate cell growth and apoptosis, including those activated in some tumor states, such as TS.5 Tuberous sclerosis is an autosomal dominant tumor syndrome that results from mutations in the tumor suppressors hamartin (TSC1) or tuberin (TSC2). Hamartin and tuberin normally suppress mTOR, which increases cell cycle progression when it is released from negative regulation. The loss of tumor suppressive function in TS leads to the formation of multiple tumors of the internal organs and skin.10 Although treatment options for TS, including facial angiofibromas, have previously been limited, reconstitution of mTOR inhibition by rapamycin may represent a targeted therapy to prevent and treat tumors.5,11

There are several recent studies that support the effectiveness of this targeted molecular approach. Bissler et al6 found that oral rapamycin when used at a dosage similar to that used in renal transplant recipients reduced the volume of visceral angiomyolipomas in patients with TS by up to 50%. Also, a patient with TS who was receiving oral rapamycin therapy because of renal transplantation simultaneously experienced regression of cutaneous angiofibromas and improved quality of life.2 However, immunosuppression resulting in opportunistic infection, elevated cholesterol levels, decreased renal function, and oral ulcers are potential adverse effects of oral rapamycin therapy. Furthermore, continued dosing may be necessary to maintain clinical benefit.6 Therefore, topical therapy would be an ideal delivery system to minimize systemic adverse effects in the treatment of cutaneous angiofibromas.

Several recent studies suggest the feasibility of topical delivery. A topical preparation of rapamycin, 8%, in a capric acid–benzyl alcohol vehicle was recently shown to penetrate normal skin and appeared to have anti-inflammatory activity in a study of 24 patients with psoriasis. One drawback to the preparation used in the clinical psoriasis study was that the vehicle may have contributed to local irritation in 3 patients.7 To avoid such local adverse effects, we used a petrolatum-based vehicle for our patient, and the treatment was very well tolerated, without signs of local irritation. Note that tacrolimus, which is chemically similar to rapamycin, also exerts its biologic function effectively in a similar vehicle. Additional study in a TS mouse model has demonstrated that topical rapamycin ointments, 0.4% and 0.8%, could inhibit tumor growth effectively12 when applied to a very large BSA, resulting in systemic absorption.

Our patient did not demonstrate detectable serum rapamycin levels after 3 months of application to her face. Furthermore, there were no changes in blood cell counts or chemistry profiles from baseline or other evidence of systemic adverse effects of rapamycin therapy. We believe that systemic toxic effects with the 1% preparation applied to a limited BSA are unlikely. Similarly, in a previous report an 8% topical preparation applied to 1% to 5% of the BSA did not result in measurable systemic levels or laboratory abnormalities in patients with psoriasis.7 The systemic absorption observed in murine studies12 could be related to the vehicle used or to the surface area treated. Because of the high BSA to body mass index, the rapamycin dosage per body mass unit was quite high in this animal model.

While the effects seen in the present case are exciting, large-scale clinical trials are needed to validate the safety and effectiveness of this novel treatment for facial angiofibromas. Specific considerations requiring further investigation include any local or systemic consequences of long-term therapy because patients may need prolonged treatment. Compliance was not an issue in our patient because of the excellent response she had to the treatment. At the time of this report, she is still using the medication daily. Therefore, we cannot presently offer practical insight into whether the lesions will recur after downtitration or discontinuation of the therapy. However, this issue certainly merits further systematic investigation because regrowth has been noted with renal angiomyolipomas after discontinuation of oral rapamycin therapy.6 Finally, further evaluation of the potential for systemic absorption should be performed, particularly with respect to smaller children and infants. Although we believe that accidental transfer of small amounts to the mouth or eyes should be considered in young children, we do not think that this will pose any serious health risk. The utility of rapamycin eye drops for treating conditions such as macular degeneration has been limited by poor absorption across the outer surface of the eye, with potential applications presently focused on ocular surface conditions such as keratoconjunctivitis sicca as a result.13

In summary, current data suggest that topical rapamycin ointment can be an effective treatment for recalcitrant facial angiofibromas in patients with TS. The treatment appears to be well tolerated with no evident local or systemic adverse effects. Furthermore, it avoids the risks of general anesthesia and surgical complications and appears to produce more sustained effects than procedural treatments. Finally, given the effects of rapamycin therapy on both angiogenesis and cell division, topical preparations may ultimately find broader application for a variety of benign (eg, infantile hemangioma) and malignant (eg, Kaposi sarcoma)14 cutaneous vascular lesions.

Correspondence: Joyce M. Teng, MD, PhD, Departments of Dermatology and Pediatrics, University of Wisconsin School of Medicine and Public Health, 1 S Park St, Seventh Floor, Madison, WI 53715 (

Accepted for Publication: February 23, 2010.

Author Contributions: Dr Teng had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Haemel and Teng. Acquisition of data: Teng. Analysis and interpretation of data: Haemel, O’Brian, and Teng. Drafting of the manuscript: Haemel, O’Brian, and Teng. Critical revision of the manuscript for important intellectual content: Haemel, O’Brian, and Teng. Administrative, technical, or material support: Haemel and Teng. Study supervision: Teng.

Financial Disclosure: None reported.

Additional Contributions: Marla Ahlgrimm, RPh, Women's Health America/Madison Pharmacy Associates, compounded the medication used in this case.



Clinicians, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Manuscripts should be prepared double-spaced with right margins nonjustified. Pages should be numbered consecutively with the title page separated from the text (see Instructions for Authors [] for information about preparation of the title page). Clinical photographs, photomicrographs, and illustrations must be sharply focused and submitted as separate JPG files with each file numbered with the figure number. Material must be accompanied by the required copyright transfer statement (see authorship form []). Preliminary inquiries regarding submissions for this feature may be submitted to Erik J. Stratman, MD ( Manuscripts should be submitted via our online manuscript submission and review system (

Boixeda  PSanchez-Miralles  EAzana  JMArrazola  JMMoreno  RLedo  A CO2, argon, and pulsed dye laser treatment of angiofibromas.  J Dermatol Surg Oncol 1994;20 (12) 808- 812PubMedGoogle ScholarCrossref
Hofbauer  GFMarcollo-Pini  ACorsenca  A  et al.  The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.  Br J Dermatol 2008;159 (2) 473- 475PubMedGoogle ScholarCrossref
Song  MGPark  KBLee  ES Resurfacing of facial angiofibromas in tuberous sclerosis patients using CO2 laser with flashscanner.  Dermatol Surg 1999;25 (12) 970- 973PubMedGoogle ScholarCrossref
Guba  Mvon Breitenbuch  PSteinbauer  M  et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.  Nat Med 2002;8 (2) 128- 135PubMedGoogle ScholarCrossref
Sabatini  DM mTOR and cancer: insights into a complex relationship.  Nat Rev Cancer 2006;6 (9) 729- 734PubMedGoogle ScholarCrossref
Bissler  JJMcCormack  FXYoung  LR  et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.  N Engl J Med 2008;358 (2) 140- 151PubMedGoogle ScholarCrossref
Ormerod  ADShah  SACopeland  POmar  GWinfield  A Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial.  Br J Dermatol 2005;152 (4) 758- 764PubMedGoogle ScholarCrossref
Hafizi  SMordi  VNAndersson  KMChester  AHYacoub  MH Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.  Vascul Pharmacol 2004;41 (4-5) 167- 176PubMedGoogle ScholarCrossref
Raichlin  EBae  JHKhalpey  Z  et al.  Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.  Circulation 2007;116 (23) 2726- 2733PubMedGoogle ScholarCrossref
Schwartz  RAFernandez  GKotulska  KJozwiak  S Tuberous sclerosis complex: advances in diagnosis, genetics, and management.  J Am Acad Dermatol 2007;57 (2) 189- 202PubMedGoogle ScholarCrossref
Paghdal  KVSchwartz  RA Sirolimus (rapamycin): from the soil of Easter Island to a bright future.  J Am Acad Dermatol 2007;57 (6) 1046- 1050PubMedGoogle ScholarCrossref
Rauktys  ALee  NLee  LDabora  SL Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.  BMC Dermatol 2008;81PubMedGoogle ScholarCrossref
Buech  GBertelmann  EPleyer  USiebenbrodt  IBorchert  HH Formulation of sirolimus eye drops and corneal permeation studies.  J Ocul Pharmacol Ther 2007;23 (3) 292- 303PubMedGoogle ScholarCrossref
Guenova  EMetzler  GHoetzenecker  WBerneburg  MRocken  M Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.  Arch Dermatol 2008;144 (5) 692- 693PubMedGoogle Scholar